Foamlab raises € 3 million growth capital to build pilot plant and scale bio-based foams: a new investment by Capricorn Industrial Biotech Fund

Foamlab B.V. has raised a funding round from a consortium of ICOS Capital, Value Factory, DOEN Ventures, Capricorn Industrial Biotech Fund, and TTT Green Tech Fund managed by SHIFT Invest. The investment enables the company to build a pilot plant, scale production, and accelerate the commercial rollout of its biobased foam materials.

Foamlab develops a new class of sustainable foams made from bacterial cellulose, a natural and renewable material grown through fermentation. Each year, millions of tonnes of fossil-based plastic foams are used in packaging, textiles, furniture, and construction-materials that generate persistent waste and are nearly impossible to recycle. Our bacterial cellulose-based foams offer a circular alternative by design: bio-based, compostable, and tuneable in their properties. From soft, textile-like foams to rigid, structural solutions, we enable high-performance applications with minimal environmental impact. By collaborating with forward-thinking partners, Foamlab accelerates the transition to a regenerative, bio-based materials economy.

The round is led by ICOS Capital, an investor focused on accelerating the transition to a sustainable and circular economy by backing scalable deeptech solutions with clear market traction. Value Factory, Stichting DOEN, Capricorn Industrial Biotech Fund, and TTT Green Tech join as co-investors.

Damien van der Bijl, Investment Director of Capricorn Industrial Biotech Fund:

• Foamlab is scaling their solution for replacing fossil-based foams with sustainable alternatives. We are impressed with the progress the team is making and look forward to supporting them in the next phase. This is the kind of technology the world needs to transition to a sustainable future, and it fits very well with the focus of our Article 9 impact fund.”

Jeroen van Rotterdam, CEO of Foamlab:

• We are very proud to bring together such a strong group of impact investors. We see growing demand for our bacterial nanocellulose foams across multiple industries. This funding enables us to scale production, serve early customers, and accelerate our path to market. Beyond capital, our investors bring hands-on support and valuable networks.”